Health Care [ 1/12 ] | Pharmaceuticals [ 10/73 ]
NASDAQ | Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases.
It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease.
The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 25 | -0.03 Increased by +85.17% | -0.07 Increased by +57.14% |
| Aug 14, 25 | -0.17 Decreased by -247.65% | -0.08 Decreased by -112.50% |
| May 14, 25 | -0.07 Increased by +68.92% | -0.10 Increased by +30.00% |
| Feb 4, 25 | -0.10 | -0.05 Decreased by -100.00% |
| Nov 11, 24 | -0.20 | - |
| Aug 13, 24 | -0.05 | - |
| Mar 31, 24 | -0.23 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -1.10 M Increased by +81.60% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -5.07 M Decreased by -249.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.18 M Increased by +65.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 18.79 M Increased by +N/A% | -2.90 M Increased by +68.93% | Decreased by -15.42% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -5.99 M Decreased by -250.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.45 M Increased by +6.54% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -6.25 M Decreased by -1.20 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -9.33 M Decreased by -1.81 K% | Decreased by N/A% Decreased by N/A% |